Use of TNF-alpha inhibitor for treatment of psoriasis

• US 8,906,373 B2
• Filed: 04/30/2014
• Issued: 12/09/2014
• Est. Priority Date: 07/19/2002
• Status: Expired due to Term

• Current Assignee: AbbVie Biotechnology Ltd. (Puerto Rico) (Abbvie Incorporated)
• Original Assignee: AbbVie Biotechnology Ltd. (Puerto Rico) (Abbvie Incorporated)
• Inventors: Banerjee, Subhashis, Hoffman, Rebecca S., Tracey, Daniel E., Chartash, Elliot K., Barchuk, William T., Yan, Philip, Salfeld, Jochen G., Weinberg, Mark, Taylor, Lori K., Spiegler, Clive E., Murtaza, Anwar, Fischkoff, Steven A., Granneman, George R.
• Primary Examiner(s): OUSPENSKI, ILIA I
• Application Number:
  US14/266,598
• Publication Number:
  US 20140286867A1
• Time in Patent Office: 223 Days
• Field of Search: None
• US Class Current: 424/145.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/70 Multivalent vaccine
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61K 49/0004 Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: C07K 16/241 Tumor Necrosis Factors
• CPC Class Codes: C07K 16/468 Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
• CPC Class Codes: C07K 2317/21 from primates, e.g. man
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention describes methods of treating erosive polyarthritis comprising administering a TNFα antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNFα antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.

Claims

1. A method of treatment of psoriasis in a patient with moderate to severe active psoriatic arthritis (PsA), comprising subcutaneously administering to said patient 40 mg adalimumab every other week, wherein said patient has ≧

3 swollen and ≧

3 tender joints prior to the treatment and has failed NSAID therapy, and wherein said patient achieves a 90% reduction of the Psoriasis Area and Severity Index Score (PASI

     90) at week 24 of the treatment.

2. The method of claim 1, wherein said patient has psoriasis in <

3% body surface area prior to the treatment.

3. The method of claim 1, wherein said patient has psoriasis in ≧

3% body surface area prior to the treatment.

6. The method of claim 1, wherein said 40 mg adalimumab is comprised in a pre-filled syringe for subcutaneous injection.

7. The method of claim 1, wherein said 40 mg adalimumab is formulated in a pharmaceutical composition and at a concentration of 50 mg/ml.

4. A method for treating chronic plaque psoriasis, comprising subcutaneously administering to a patient with chronic plaque psoriasis 40 mg adalimumab every other week.

5. The method of claim 4, wherein said patient has moderate to severe chronic plaque psoriasis.

8. The method of claim 5, wherein said 40 mg adalimumab is comprised in a pre-filled syringe for subcutaneous injection.

9. The method of claim 5, wherein said 40 mg adalimumab is formulated in a pharmaceutical composition and at a concentration of 50 mg/ml.